中文 | English

Company profile

Lingmed Ltd was founded in 2013 in Hong Kong, currently we have offices in Shanghai, Beijing, Munich and Amsterdam. Firstly, Lingmed promotes leading intelligence databases for healthcare professionals to make better decisions; Secondly, Lingmed connects innovation between East and West with its business development service under the Linkedbio brand

Lingmed support cross-border transactions including fund raising, M&A and alliance management. We also support our clients on the identification of innovations and the management of suitable CROs, CDMOs to conduct Clinical Trials in the EU or China

Lingmed’s Products and Services have been recognized by Fortune 500 multinational pharma and device companies as well as Chinese local big pharmacos


Company strategy
In the 1st five years we brought renowned intelligence databases into China, namely EvaluatePharma from the UK and Biotechgate from Switzerland; in the 2nd five years Lingmed has started partnering services under the Linkedbio Partnering brand and made multiple cross-border deals; in the 3rd five years, Lingmed will develop its own in-house innovative database with the focus on Asia pacific innovations – Linkedbio Database and cross-border deal making and communication

Our missions
- Help the pharmaceutical industry to improve it’s productivity, to make better decisions with intelligence databases
- Connect innovative healthcare products between East and West to improve patients life quality and save lives

Our values

Efficiency, Passion, Integrity, Learning, Team work

Company History

Year Milestone
2023 Lingmed launched its in-house developed Linkedbio Database, focus on innovation from Asia-Pacific
2023 Lingmed's No. 12 valuation workshop back to in person in Shanghai
2022 Lingmed signed exclusive BD agent agreement to support Adalta to find a China partner for their CAR-T related asset
2022 Lingmed hosted No. 11 Product and Company valuation workshop online
2021 Lingmed signed exclusive BD agent agreement to support Oncostellae to find a China partner for their gastrointestinal asset
2021 Lingmed signed exclusive BD agent agreement to support Nektr to find a China partner for their fungal infection asset
2021 Lingmed was responsible for an oncology-related licensing deal for a US biotech with Qilu Pharma for China
2020 Lingmed started “Biotech showcase” at the monthly webinar
2020 Linkedbio Partnering assets and initial analysis goes "live" online
2019 Lingmed monthly webinars gained public recognition in China and Europe
2019 Lingmed successfully organized Chinabio conference post gala dinner “After Party” at rooftop of Mint in Shanghai
2018 Lingmed opened its first oversea office in Munich, Germany
2018 Lingmed signed strategic partnership to further support China clients with Healthshare in Beijing
2017 Lingmed launched Linkedbio partnering services together with Pharmaplus to connect innovation between EU and China
2017 Lingmed acquired GBI's Source China EU market exclusive sales rights
2016 Lingmed launched add on services - Linkedbio analytical to support China clients with analysis and insights
2015 Lingmed acquired EvaluatePharma's China market exclusive sales rights
2015 Lingmed developed new sales processes with Advisor Sam
2015-2018 Lingmed attended JP Morgan, Bio Europe, China bio and local conferences and events to promote partners’ branded products
2014 Lingmed registered China legal entity
2014 Lingmed successfully organized the first valuation workshop in China
2013 Lingmed founded in Hong Kong
2013 Lingmed acquired Biotechgate from Switzerland China market exclusive sales rights
2013 Lingmed started collaborating with GBI on Source China domestic market sales

Lingmed team events at a glance


Team dinner to discuss sales strategy

Valuation workshop working team in Shanghai

Team building – a day sailing on the lake

Speaking at domestic conference

Lingmed booth at conferences

Lingmed office

Lingmed at JP Morgan Conference

Team building dinner
©Copyright 2013 - Lingmed Limited